ROARABLE
FREE $100K
My Trading Account β†’
β–Ύ
Trading Profile Active
Active Trader
Verified Trader
⚑ My $100K Trading Account β†’ β˜… My Saved Watchlist β†’
🟒 My $100K Account β†’ Today Screener Big Ideas Track Record πŸ’° $100K Arena 🎲 Predictions πŸ›οΈ Insiders 8 Analysts
Stock Ratings / Health Care / HSIC
OSCR (53) CAI (73) MOH (57) GRAL (54) ⌘ Pro Terminal β†’

Henry Schein Inc. (HSIC) β€” RQD Stock Rating Cockpit

$86.62 +2.05% NASDAQ β€’ Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $86.78

Henry Schein Inc. (HSIC) carries a Roarable Rating of D+ (Sell) with 58/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D+ β€’ SELL / AVOID Cap $9.46B
πŸ“€ Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚑ INSTANT AI QUANT PREVIEW β€’ $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on HSIC Below β€” or Connect Your Own ChatGPT / Claude
πŸ€– Mara Quenwick β€’ AI Quant Lead (Click for Instant Brief) Is HSIC stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
β–Ό

As of 2026-11-03, Henry Schein Inc. (NASDAQ: HSIC) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 58/100 at a spot price of $86.62 (+2.05% 1D, market cap $9.46B). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 11/20, SEC Balance-Sheet Forensics 14/20, FRED Macro Regime Fit 12/20, and Executive Insider Alignment 12/20. Across 1015 tracked Health Care issuers, HSIC ranks #180 in composite RQD confidence.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Ellis Vennor β€’ AI Peer & Flow Quant (Click for Instant Brief) How does HSIC compare to OSCR and CAI in the Health Care sector?
β–Ό

Within the Health Care sector (Medical Specialities), HSIC carries a Roarable D+ (58/100 RQD), trailing P/E of 23.0x, gross margin of 31.1%, and ROIC of 11.2%. By comparison, OSCR (Oscar Health Inc.) holds a D+ grade (53/100 RQD, P/E N/A, ROIC -35.0%, cap $9.37B) and CAI (Caris Life Sciences Inc.) posts a B grade (73/100 RQD, P/E N/A, ROIC 4.4%, cap $9.70B). Among the 5-stock peer group, MOH leads on earnings multiple (22.0x) while MOH leads on capital efficiency (17.2% ROIC).

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Gideon Ashmere β€’ AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for HSIC?
β–Ό

Per HSIC's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-27, CIK 0001000228), Henry Schein Inc. generated $13.18B in revenue (+4.0% YoY), $419.0M in net income, and $118.7M in free cash flow against $11.21B in total assets and $2.89B in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run. Institutional options positioning shows a 50% call / 50% put premium split.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists β€” not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
πŸ›‘οΈ Portfolio Crash X-Ray
EXT / AFTER-HRS: $86.78 (+0.18%)🧬 Disciplined Float (-0.04% YoY Shares)βš™οΈ Cash Engine: 9/20 (D) β€’ 0.9% FCF Margin
Verify 90D Bucket Audit β†’
πŸ“Š Historical Track Record: Scores of 58/100 (D+) historically posted market-perform odds over rolling 90-day windows (+0.0% avg 90D alpha vs SPY β€’ 52.7% hit rate β€” wait for RQD β‰₯ 70 breakout).
Audit Bucket Track Record β†’
RQD QUANT TACHOMETERSELL / AVOID β€’ D+
025507510058
Quant Analyst Panel Split (Battleground)
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) β€” not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw D+ Β· Rk C
Cash (9)Whales (11)SEC (14)Macro (12)CEO (12)
Each axis scored 0–20
12M PRICE TARGET CONE+0% Base Target
$102 Bull$87 Base$68 Bear
πŸ“¬ FREE HSIC RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: β€” (No Active Options Snapshot on file for HSIC)Realized 20D OHLCV Swing Band: Β±4.8%
Deterministic 5-Pillar Attribution (58/100 Composite)
πŸ” WHY HSIC SCORES 58/100 (D+) β€” TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
β–² #1 Bullish Driver: SEC 10-K Forensic Risk+14/20 pts (24% of score)

Altman Z-Score 2.81 (WATCH ZONE (1.8–3.0)) β€’ Piotroski F-Score 7/9

β–² #2 Bullish Driver: Macro Regime Fit+12/20 pts (21% of score)

FRED Regime Γ— Technicals: 81% of 52W Range β€’ RSI-14 at 47.5 (NEUTRAL RANGE)

β–Ό #1 Drag / Risk Factor: Cash Engine Quality9/20 pts (-11 pt drag)

Capital intensity & 5% operating margin leave 11 pts on the table

πŸ“ˆ PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 β†’ Q2 β†’ Q3 β†’ Current
Q1 (-3Q)
50
Grade C-$85.56-0.6% Next Q
Q2 (-2Q)
53
Grade C-$85.01-0.1% Next Q
Q3 (-1Q)
55
Grade C$84.96+2% Next Q
Current
58
Grade D+$86.62+0% Hist 90D Ξ±
Trajectory: C- (50) β†’ D+ (58)Full Audit β†’
βš”οΈ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

βš”οΈ Adversarial Opposing Case: Why the HSIC Bull Thesis Could Fail

Gideon Ashmere Forensic Desk β†’

Even with a 58/100 (D+) score, HSIC faces multiple-compression risk if 23.0x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Broader market pullbacks can still drag down strong stocks in the short run.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Disciplined Float (-0.04% YoY Shares) β€” any gross margin slip below 28.6% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($86.33) or 200D SMA ($81.17) invalidates the momentum regime and cuts Target Base ($86.62) toward Bear Floor ($67.56).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $HSICβ€’ $2.4M Crowd Pool β€’ Kalshi / Polymarket Composite
Contract: β€œHSIC Beats Next Quarter EPS Consensus (Dec 26, 2026) & Holds Above 200D SMA”
YES 58%NO 42%Trade / Inspect Odds β†’
RSI-14 MOMENTUMNEUTRAL RANGE
47.530 Oversold Β· 70 Hot
ALTMAN-Z SHIELDWATCH ZONE (1.8–3.0)
2.81>3.0 Fortress Safe
PIOTROSKI F-SCOREHIGH QUALITY (7–9)
7 / 99-Pt Accounting
52-WEEK LASER RANGE81% OF RANGE
L: $63$86.62H: $92
1. Money & Cash Health● WEAK
Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: DRQD 9 / 20
2. Big Money & Insiders● NEUTRAL
Are whales & executives buying or selling?

Big funds and company insiders are mostly holding steady without aggressive buying or panic selling.

Factor Grade: D+RQD 23 / 40
3. Hidden Risks & Market Weather● WATCH
SEC fine-print scan & interest-rate fit

No major SEC filing blowups, though current interest rates and Fed liquidity call for normal position sizing.

Factor Grade: CRQD 26 / 40
MULTI-MODEL QUANT PANEL DELIBERATION

Quant Analyst Panel Split (Battleground) on HSIC

Cash & Moat Bull AI
ROIC & Free Cash Flow Model
BEARISH (45)

11.2% ROIC with 31.1% gross margin and 1.23% FCF yield.

SEC Forensic Auditor AI
10-K Accruals & Altman-Z Guard
BULLISH (70)

Altman-Z 2.81 and Piotroski 7/9 pass balance-sheet audit.

Whale & Macro Hawk AI
Options Skew, 13F & Fed NetLiq
NEUTRAL (58)

23/40 institutional & smart-money positioning score with 12/20 macro alignment.

Bull Case: Why Buyers Like HSIC
  • βœ“Established market leader in Health Care with deep daily trading liquidity.
Bear Case: What Could Go Wrong
  • !Broader market pullbacks can still drag down strong stocks in the short run.
ON-DEMAND RQD QUANT WORKSHOP β€’ SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring HSIC)

  • βœ“Walkthrough of HSIC's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • βœ“3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • βœ“Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) β†’$100K Arena
HSIC // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +20.27%⚑ TESTING RESISTANCE
2026-11-03O $86.44H $86.62L $84.88C $86.62VOL 1.20M
RES: $86.59SUP: $78.03SMA50: $86.33SMA200: $81.17
$93.82$87.01$80.21$73.40$66.59RES $86.59SUP $78.03$86.622026-05-042026-06-182026-08-052026-09-212026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

HSIC Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

πŸ¦‹ HSIC Butterfly Map β†’ + Track HSIC β†’
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
16.8%/yr Implied 5Y Growth

vs. +4.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on HSIC today. View full Setup Ledger β†’

πŸ¦‹ Documented & Second-Order Butterfly Connections Open Graph β†’

No direct multi-tier Butterfly edges indexed yet for HSIC. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for HSIC today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk β†’
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT β€’ SEC EDGAR XBRL Γ— RQD PEER BENCHMARK

πŸ“Š Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (HSIC)

Health Care Rank #180 of 1015 βš”οΈ OSCR vs HSIC Full Matrix β†’

1. Head-to-Head Health Care Peer Comparison (HSIC vs. OSCR, CAI, MOH, GRAL)

Industry: Medical Specialities (41 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Henry Schein Inc. (HSIC) ranks #180 by composite RQD confidence (58/100, grade D+) and #115 by equity capitalization ($9.46B). Within this direct 5-issuer industry benchmark cohort, MOH leads on earnings valuation at 22.0x trailing P/E, while MOH leads on capital efficiency and profitability with 17.2% ROIC and 13.1% gross margin. CAI currently holds the highest overall quantitative score in the immediate peer group at 73/100 (B) compared with HSIC at 58/100 (D+).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
HSIC ACTIVE
Henry Schein Inc.
D+ 58/100 23.0x 31.1% 11.2% +2.05% $9.46B Benchmark Subject
OSCR
Oscar Health Inc.
D+ 53/100 β€” β€” -35.0% +2.07% $9.37B /oscr-vs-hsic β†’
CAI
Caris Life Sciences Inc.
B 73/100 β€” β€” 4.4% -6.50% $9.70B /cai-vs-hsic β†’
MOH
Molina Healthcare Inc
D+ 57/100 22.0x 13.1% 17.2% +1.79% $10.69B /moh-vs-hsic β†’
GRAL
GRAIL Inc.
D+ 54/100 β€” β€” -18.0% -6.74% $6.41B /gral-vs-hsic β†’

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K β€’ FILED 2025-12-27 β€’ CIK 0001000228 β†—

In its most recent audited fiscal period (FY2025, filed 2025-12-27), Henry Schein Inc. (HSIC) reported GAAP revenue of $13.18B (+4.0% vs. FY2024 revenue of $12.67B , and +6.8% cumulative change since FY2023) , GAAP net income of $419.0M, operating cash flow of $712.0M, and free cash flow of $118.7M (-57.3% YoY). On the balance sheet, HSIC closed FY2025 with $11.21B in total assets against $2.89B in total debt (Altman Z-Score: 2.81, Piotroski F-Score: 7/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-27 $13.18B $419.0M $712.0M $118.7M $11.21B $2.89B
FY2024 (FY) 2024-12-28 $12.67B $398.0M $848.0M $277.7M $10.22B $2.42B
FY2023 (FY) 2023-12-30 $12.34B $436.0M $500.0M -$55.3M $14.81B $3.46B

3. HSIC Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

βœ“ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is HSIC stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Henry Schein Inc. (NASDAQ: HSIC) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 58/100 at a spot price of $86.62 (+2.05% 1D, market cap $9.46B). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 11/20, SEC Balance-Sheet Forensics 14/20, FRED Macro Regime Fit 12/20, and Executive Insider Alignment 12/20. Across 1015 tracked Health Care issuers, HSIC ranks #180 in composite RQD confidence.

How does HSIC compare to OSCR and CAI in the Health Care sector?

Within the Health Care sector (Medical Specialities), HSIC carries a Roarable D+ (58/100 RQD), trailing P/E of 23.0x, gross margin of 31.1%, and ROIC of 11.2%. By comparison, OSCR (Oscar Health Inc.) holds a D+ grade (53/100 RQD, P/E N/A, ROIC -35.0%, cap $9.37B) and CAI (Caris Life Sciences Inc.) posts a B grade (73/100 RQD, P/E N/A, ROIC 4.4%, cap $9.70B). Among the 5-stock peer group, MOH leads on earnings multiple (22.0x) while MOH leads on capital efficiency (17.2% ROIC).

What are the biggest fundamental strengths and SEC risk factors for HSIC?

Per HSIC's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-27, CIK 0001000228), Henry Schein Inc. generated $13.18B in revenue (+4.0% YoY), $419.0M in net income, and $118.7M in free cash flow against $11.21B in total assets and $2.89B in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run. Institutional options positioning shows a 50% call / 50% put premium split.

Where is HSIC trading relative to its 50-day, 200-day, and 52-week technical levels?

HSIC last traded at $86.62 (+2.05% on volume of 2,501,946 shares), positioning the stock +0.34% above its 50-day simple moving average ($86.33) and +6.71% above its 200-day simple moving average ($81.17). Across its 52-week range of $63.04 to $92.18, HSIC sits at the 80.9% percentile with a 14-day RSI of 47.5 (NEUTRAL RANGE) and an implied next-earnings move of Β±4.8% ($82.46 to $90.78).

Direct Sub-Reports: HSIC RQD Cockpit HSIC 12M Forecast HSIC Earnings & Move HSIC Dividends & DRIP HSIC Insiders & 13F HSIC Whale Options HSIC Profit Sankey HSIC News & Why
ROARABLE RATING BRIEF β€’ RQD 58/100 (D+) βœ“ SEC XBRL & RQD VERIFIED

HSIC β€” Henry Schein Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-27

1. Roarable Rating Brief: What This Means to a Prospective Investor

Henry Schein Inc. (HSIC) earns a live Roarable RQD composite score of 58/100, corresponding to a D+ letter grade (Roarable Sell) at a spot price of $86.62 (+2.05% 1D, market capitalization $9.46B).

  • Fundamental Cash Engine (9/20): Anchored by return on invested capital (ROIC) of 11.2%, gross margin of 31.1%, operating margin of 5.0%, and free cash flow yield of 1.23%.
  • Whale 13F & Options Flow (11/20) + Insider Conviction (12/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (12/20) + Forensic Balance Sheet (14/20): Incorporates a 0.89x equity beta, Altman Z-Score of 2.81, Piotroski F-Score of 7/9, and Debt/Equity of 0.83x.

2. Business Model, Unit Margins & SEC Financial Trajectory

Henry Schein Inc. Is a NASDAQ-listed issuer in the Health Care sector, operating within the Medical Specialities industry, profile. The company's market capitalization is $9.6B per the market data.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-27), Henry Schein Inc. (HSIC) reported $13.18B in annual revenue (up from $12.67B in FY2024, +4.0% YoY) and $419.0M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($12.34B revenue, $436.0M net income) through FY2025, HSIC scaled operating cash flow to $712.0M and free cash flow to $118.7M, backed by $11.21B in total assets against $2.89B in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • πŸ‚ Primary Bull Case (D+ β€’ RQD 58/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of 1.23% and institutional whale pillar of 11/20. With Fundamental Cash Engine at 9/20 and Institutional Whale Flow at 11/20, sustained execution supports upside toward the upper end of the $63.04 – $92.18 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Broader market pullbacks can still drag down strong stocks in the short run. Investors must weigh 23.0x trailing P/E and 9.5x EV/EBITDA against 5.0% operating margins and a 0.89x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Medical Specialities (Health Care), HSIC carries a macro regime beta of 0.89 and gross margin of 31.1%.

  • Key Question #1: Can HSIC sustain or expand its 5.0% operating margin and 11.2% ROIC against Medical Specialities peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $13.18B and free cash flow of $118.7M, how will capital allocation balance growth reinvestment against $2.89B in total debt?
  • Key Question #3: How sensitive is HSIC's 21.4x forward P/E multiple to Health Care capital spending cycles and macro interest-rate shifts (Beta 0.89x)?

HSIC Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Henry Schein Inc. (HSIC) β€’ Click "Debate This Headline" to argue it in the Roar Pit below

πŸ’¬ Jump to HSIC Debate Forum (3) ↓
πŸ”₯ THE ROAR PIT β€’ LIVE COMMUNITY DEBATE 3 Active Posts & Replies

HSIC Bull vs. Bear Conversation Board β€” What's Your Call at $86.62?

πŸ‚ 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON HSIC 🐻 33% BEARISH CONVICTION
1. Pick Your Side on HSIC:
πŸ’‘ Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
CA CashFlowKing RQD DEBATE OPENER β€’ FCF Compounder Hunter πŸ‚ BULLISH 🎯 Target: $112.04 (+32.0%)
πŸ“Œ Pinned Debate

Forensic balance sheet scores 14 of 20 with Altman Z 2.81, Piotroski F 7/9, and Debt/Equity 0.83, supported by a 0.89 beta.

Long HSIC at $84.88 targeting $112.04. Forensic balance sheet scores 14 of 20 with Altman Z 2.81, Piotroski F 7/9, and Debt/Equity 0.83, supported by a 0.89 beta.. Institutional whale score is 11/20 and the risk/reward vs. the $68.00 52-week low is skewed heavily in favor of bulls.

CapAlloc_Nerd πŸ‚ BULL

@CashFlowKing Agree on the RQD 58/100 quality, though with 0.89 beta I'm scaling in with half-size at $84.88 and keeping dry powder in case we test $78.94.

BE BearTrap_Alert RQD DEBATE OPENER β€’ Cycle Peak Watcher 🐻 BEARISH 🎯 Target: $64.51 (-24.0%)
Spot @ $84.88

Fundamental Cash Engine scores only 9 of 20 with a 1.23% FCF yield against a trailing P/E of 23.

Sitting on the sidelines or leaning short HSIC above $84.88. Fundamental Cash Engine scores only 9 of 20 with a 1.23% FCF yield against a trailing P/E of 23.. Until Fundamental Cash Engine (9/20) and FCF yield (1.23%) inflect higher, upside is capped near $92.18.

LIVE TAPE